NEJM Journal Watch
An editorially independent, go-to-source for clinicians since 1987, NEJM Journal Watch is among the principal products of NEJM Group. The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes. NEJM Journal Watch helps clinicians save time and stay informed by providing them with brief, clearly written, clinically focused perspectives on the medical developments that affect practice. Its editors -- practicing physicians and thought leaders in their fields -- survey the medical literature, select the most important research and guidelines, distill them into focused summaries, and frame them in a clinical context. In addition, NEJM Journal Watch covers the most important medical news, drug information, and public health alerts.
For more information, visit www.jwatch.org.
Latest by NEJM Journal Watch
Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective? Paul E. Sax, M.D., offers a revised -- and deliberately provocative -- recommendation.
As a Strategy for HIV Prevention, Disabling the CCR5 Gene in Embryos Implanted in HIV-Negative Mothers Makes Zero Sense
Paul Sax, M.D., puts it bluntly: "[I]t makes zero sense to do this since the babies aren't at risk of getting HIV to begin with."
HIV and HCV Treatment, Shorter Antibiotic Courses, Malaria-Sniffing Dogs, and Other ID and HIV Reasons to Be Grateful, 2018 Edition
Just in time for Thanksgiving, Paul Sax, M.D., provides a rundown of developments that infectious disease and HIV specialists can be grateful for over the past year.
"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.
"I truly believe that HIV care remains an extraordinarily gratifying aspect of ID clinical practice," Paul Sax, M.D., writes. "Which is why it’s critical that ID doctors continue to do it."
Paul Sax, M.D., provides highlights of the important and interesting studies that caught his eye at AIDS 2018.
Paul Sax, M.D., says that while most patients prefer the simplicity of having one pill, one prescription, and one co-pay, the new Symtuza (D/C/F/TAF) tablet faces several challenges that may limit widespread adoption.
Earlier this year, urology resident Philip Cheng, M.D., appeared on the front page of The New York Times explaining his situation. Now, in a podcast, he tells Paul Sax, M.D., more about himself and the events surrounding his decision to go public....
There are several reasons why this warning is important -- and why the best treatment for women with HIV who want children remains an open question.
After the departure from clinical practice of three colleagues, Paul Sax, M.D., reflects on the state of U.S. health care and its frustrating "medicine-as-a-business" model.